



SRL 6067  
PATENT

1614  
#5  
8/15/00  
RECEIVED

AUG 16 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Gary S. Jacob

Serial No. 09/023,401

Filed December 12, 1998

For USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL  
COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS  
VIRUS INFECTIONS

August 11, 2000

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit the attached PTO Form 1449 (modified) for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record herein.

The references listed on the attached PTO-1449 have been submitted in related application Serial No. 09/249,220 and, therefore, in accordance with MPEP 609, are not being provided at this time.

It is believed that this Second Supplemental Information Disclosure Statement is being submitted prior to the issuance of a first Office action. However, if there are any fees associated with this filing, the Commissioner is hereby authorized to charge the fee to Deposit Account No. 19-1345.


SRL 6067  
PATENT

RECEIVED

AUG 16 2000

TECH CENTER 1600/2900


Respectfully submitted,



John K. Roedel, Jr., Reg. No. 25,914  
SENNIGER, POWERS, LEAVITT & ROEDEL  
One Metropolitan Square, 16th Floor  
St. Louis, Missouri 63102  
(314) 231-5400

CERTIFICATE OF MAILING

I certify that this Second Supplemental Information Disclosure Statement and attached PTO Form 1449 is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 11th day of August, 2000.



Cindy A. Ard

JKRcaa  
\*Attachments